Dr Joseph Sparano speaks to ecancer about multimodal artificial intelligence (AI) models integrating image, clinical, and molecular data for predicting early and late breast cancer recurrence in TAILORx

Using data from thousands of TAILORx participants, researchers developed AI models integrating clinical data, molecular signatures, and digital pathology to improve prediction of distant recurrence risk in HR+/HER2- early breast cancer.

While Oncotype DX remained useful for early recurrence, it showed limited value beyond 5 years.

The multimodal ICM+ AI model significantly improved accuracy for overall and late recurrence prediction compared to traditional tools, helping better identify which patients may need extended endocrine therapy and enabling more personalised long-term risk assessment.